Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 483

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 483
---
 by regulatory agencies; |

| • |     | the phase of development of the product candidate; and |

| • |     | the efficacy and safety profile of the product candidate. |

Acquired In-ProcessResearch and Development (“IPR&D”) Acquired in-processresearch and development expenses consist of existing research and development projects at the time of the acquisition. Projects that qualify as IPR&D assets represent those that have not yet reached technological feasibility and have no alternative future use. TuHURA acquisitions of assets have included IPR&D assets that had not yet reached technological feasibility and had no alternative future use, which resulted in a write-offof these IPR&D assets to acquired in-processresearch and development expenses in TuHURA’s consolidated statement of operations. 307

General and Administrative Expenses General and administrative expenses consist primarily of salaries and employee-related costs, including stock-based compensation, for personnel in TuHURA’s executive, finance, and other administrative functions. Other significant costs include facility related costs, legal fees relating to intellectual property and corporate matters, professional fees for accounting and consulting services and insurance costs. TuHURA anticipates that its general and administrative expenses will increase in the future to support TuHURA’ continued research and development activities, and, if any product candidates receive marketing approval, commercialization activities. TuHURA also anticipates increased expenses related to audit, legal, regulatory, and tax-relatedservices associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums and investor relations costs associated with operating as a public company. Other Income (Expense) Other income (expense) consists of interest income on TuHURA’s cash and cash equivalents, interest expense on borrowings under TuHURA’s convertible note agreements, and non-cashchanges in the fair value of TuHURA’s derivative liability associated with the make-whole premium on TuHURA’s convertible notes. Other income (expense) also included grant income from TuHURA’s NIH-fundedresearch grants completed in May 2023, employee retention tax credit for companies with employees affected during the COVID-19pandemic, and forgiveness of a paycheck protection program loan in April 2022. Preferred Series A Cash Dividend Preferred Series A cash dividend represents a cash dividend payable to Valent Technologies, LLC, the holder of TuHURA’s Series A Preferred Stock. Effective September 30, 2014, Kintara filed a Certificate of Designation of Series A Preferred Stock with the Secretary of State of Nevada, pursuant to which, Kintara designated and